Press Room


    Press Release - October 15, 2001

    Pheromone Sciences Corp. Receives European Regulatory Approval

    CE Mark provides gateway to European Marketplace for PSC Fertility Monitor�¢ï¿½�¢

    Pheromone Sciences Corp (CDNX:PHS), today announced that it has received CE mark regulatory approval for its PSC Fertility Monitor�¢ï¿½�¢. The CE Mark provides a regulatory gateway to the European marketplace thereby allowing the Company to proceed to attract licensees for marketing and distribution rights to the device in the various member countries of the European Community. It enables the Company to market the PSC Fertility Monitor�¢ï¿½�¢ without having to undergo country specific registration.

    "We are excited about this as it represents an important step in the Company's product development plans" said Christopher Neuman, President & CEO of Pheromone. "With this approval, our potential market has been broadened which no doubt will lead to increased revenue."

    As part of its strategy to make the PSC Fertility Monitor�¢ï¿½�¢ available to women who would value the convenience of use and advance notice of their peak fertility and ovulation days, the company had conducted the prerequisite testing required to file for the CE mark as a first step in bringing the PSC Fertility Monitor to the European Market.

    The PSC Fertility Monitor�¢ï¿½�¢ offers a new user- friendly option in family planning. This product, which is housed in a modern styled wristwatch like device with an LCD readout, is worn at night during sleeping hours. The PSC Fertility Monitor�¢ï¿½�¢ is a proprietary, non- invasive device which predicts ovulation by measuring ion changes on the surface of the skin. The device incorporates an interactive microprocessor combined with a biosensor enabling it to take up to 12 daily measurements from the skin surface and to evaluate the data in order to predict the status of the user, with 4 days advance notice, as being not-fertile, fertile or ovulating. Results can be viewed at any time on the LCD screen of the device or as a computer- generated graphical printout for medical professionals.

    "This is a great opportunity. We are currently in discussions with several companies about licenses. These companies are well established firms that have the knowledge and understanding of the European Market that will help us market and distribute the PSC Fertility Monitor�¢ï¿½�¢ widely in this new area" said Neuman.

    Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

    Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.


    Lorne Woods 1(800) 937-3095


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News